Search Results

Jennifer Huff and Jacqui Mellott are two of Johnson & Johnson’s oncology clinical educators—a team of 50 nurses who visit hospitals and infusion centers to help providers understand and stay up to date with treatments.

73% of surveyed HCPs say there’s a gap between the availability of new, cutting-edge treatments and their successful implementation in clinical practice; 3 in 4 oncologists find the pace of new treatment development overwhelming Insights will boost Johnson & Johnson’s strong approach to supporting oncologists with the resources and opportunities needed to enhance patient care and stay informed on emerging treatments.

TREMFYA® subcutaneous induction demonstrates significant rates of clinical remission and endoscopic improvement at Week 24 in ulcerative colitis Findings build on recent FDA-approval of both routes of administration for induction therapy with TREMFYA® in Crohn’s disease

Data from the QUASAR long-term extension study demonstrate more than 70% of patients were in clinical remission and more than 40% of patients were in endoscopic remission at Week 92

What 500 oncology professionals say about the current state of cancer care

First and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older IMAAVY delivered rapid and substantial reduction in immunoglobulin G (IgG) levels, one of the root causes of gMG, in both the adult and pediatric pivotal studies gMG patients taking IMAAVY demonstrated 20 months of lasting disease control and symptom relief in the pivotal Vivacity-MG3 study and ongoing open-label extension (OLE)

First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumors, demonstrating the potential for bladder preservation with 94 percent of patients avoiding radical cystectomy 95 percent progression-free survival rate at 9-months signals the promise of TAR-200 in this high-risk patient population

Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than half of responders remaining cancer-free at one year after CR Results reinforce potential of TAR-200 to transform outcomes for certain types of BCG-unresponsive, high-risk non-muscle invasive bladder cancer